Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA agrees on ''black triangle'' for new drugs launched in EU

This article was originally published in Scrip

Executive Summary

All new products launched in the EU will have to display a black inverted triangle on their product information denoting that the product is subject to additional monitoring, if the European Commission accepts the advice of the new pharmacovigilance committee (PRAC) at the European Medicines Agency.

You may also be interested in...



Ireland Embarks On New Stage Of Drug Verification System

The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage. 

EU & US At Odds Over Merck’s Keytruda

EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.

First African Approvals For Merck’s Ebola Vaccine

Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa. 

Topics

UsernamePublicRestriction

Register

SC019398

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel